Navigation Links
Synthetic peptoids hold forth promise for new antibiotics
Date:3/7/2008

Drug-resistant bacterial infections are a growing concern, and much research has been devoted to finding new classes of antibiotics to fight them.

Stanford researchers may have found some answers in peptoids, a class of manmade molecules very similar to natural proteins that play an important role in the human immune system.

"Peptoids could be an entirely new class of antibiotic drugs, which would be hugely important," said Annelise Barron, associate professor of bioengineering at Stanford and senior author of a paper describing the research in the Feb. 26 issue of the Proceedings of the National Academy of Sciences.

Natural peptides

Anti-microbial peptides are evolutionarily ancient infection fighters found in organisms from grasses to amphibians to humans. In the human body, the peptides show up in the mouth, lungs and intestines, and in body fluids like sweat and tears. Anti-microbial peptides target a variety of pathogens and generally kill by punching holes in the invaders' cell membranes.

"You can think of these types of antibiotics as the body's 'land mines' against invading pathogens," Barron said.

Because of this, bacterial resistance to the peptides is rarely observed. Bacteria can thwart other anti-microbial drugs by inactivating the drug, pumping it out of the cell, altering the drug's binding site so it is no longer recognized or working around the specific cell part attacked by the drug.

But it is much tougher for bacteria to develop resistance to the damage caused by anti-microbial peptides. "The bacteria can't fundamentally alter their entire outer membrane," Barron said.

Such peptides seem like a natural choice for new antibiotics. One type showed promise in the treatment of diabetic foot ulcers. Unfortunately, their applicability has been limited so far to topical use; natural peptides are quickly degraded in the stomach. Thus, a peptide-based drug must be injected rather than swallowed. The peptides are quickly broken down in the bloodstream as well, and must therefore be injected in high concentrations.

Promise of peptoids

Peptoids are synthetic molecules -- oligomers -- with structures that are similar to those of anti-microbial peptides, and offer the potential to overcome many of the problems associated with the natural molecules. Peptoids are much less susceptible to degradation in the stomach and bloodstream than peptides, so they will last longer in the body. They are also less expensive to produce than peptides, Barron said.

Barron and her colleagues had these peptoids tested against six strains of pathogenic bacteria. The peptoids showed anti-bacterial properties almost identical to those of the natural peptides.

"They did beautifully," Barron said. "They appear to be broad-spectrum antibiotics that interact and interfere with bacterial cell membranes analogously to the way these peptides do."

To see if the peptoids would be harmful to human cells, the researchers combined them with human red blood cells in the laboratory. They also mixed them with mammalian lung cells and skin cells. At their active concentrations, the peptoids left the mammalian cells unharmed.

Barron said that the next step is testing the peptoids in animal models of bacterial infection, and studies with mice are under way with collaborators.

"It's an exciting area," she said. "Society desperately needs new antibiotics, and I think this family of molecules has huge clinical promise."


'/>"/>

Contact: Louis Bergeron
louisb3@stanford.edu
650-725-1944
Stanford University
Source:Eurekalert

Related medicine news :

1. Duramed Launches New Indication for ENJUVIA(TM) (Synthetic Conjugated Estrogens, B) at North American Menopause Society Annual Meeting
2. Varian, Inc. Offers New Products for the Rapid Purification of Synthetic Oligonucleotides.
3. Collagen Matrix, Inc. Receives FDA 510(k) Clearance for SynOss(TM) Synthetic Mineral Bone Graft Material
4. New understanding of how big molecules bind will lead to better drugs, synthetic organic materials
5. Boise(R) BEWARE(TM) Meets New Federal Guidelines Set Forth by Medicaid
6. New study shows promise in reducing surgical risks associated with surgical bleeding
7. New Heart Pump Shows Promise in Trial
8. Blood-flow detector software show promise in preventing brain damage
9. The 7 Key Questions About the Schwarzenegger/Nunez Health Care Compromise
10. Antidepressant shows early promise in treating agitation and psychotic symptoms of dementia
11. Genetics Hold Promise, Challenges for Cancer Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Talented ... the lowdown on sciatica in a new episode of "Success Files," which is ... events and innovation and investigates each subject in-depth with passion and integrity. , ...
(Date:10/12/2017)... ... 12, 2017 , ... First Healthcare Compliance (FHC), an industry ... a range of technology and learning solutions at the 68th Annual American Healthcare ... be held October 14–18, 2017 at the Mandalay Bay Resort in Las Vegas, ...
(Date:10/12/2017)... ... , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s ... design of the shoulder pad. The shoulder pad provides optimal support and full ... while using cold therapy. By utilizing ice and water that is circulated from an ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... Hair Restoration, has recently contributed a medical article to the newly revamped ... Dr. Mohebi’s article spotlights the hair transplant procedure known as Follicular Unit ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... of Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite ... program on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... , Sept. 27, 2017  Commended for their devotion ... notable awards. Ranked as number one in the South Florida ... time in Inc. 5000 yearly list, the national specialty pharmacy ... Armando Bardisa will soon be honored by SFBJ ... Set to receive his award in ...
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., ... analytics, today announced that it has been ranked #1 by ... Black Book™ Rankings 2017 User Survey. ZirMed was recognized ... for large hospitals and medical centers over 200 beds and ... Book,s healthcare technology user survey history. ...
Breaking Medicine Technology: